Canadian Men’s Health Foundation expands MindFit Toolkit to support more men with anxiety and depression
January 19, 2023 08:00 ET
|
Canadian Men's Health Foundation
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Men’s Health Foundation (CMHF) announced today new and expanded mental health resources for their MindFit Toolkit...
FDA Clears Magstim Transcranial Magnetic Stimulation for Obsessive Compulsive Disorder
January 18, 2023 13:05 ET
|
Magstim EGI
MINNEAPOLIS, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA...
Mental Health Technologies Celebrates Mental Wellness Month
January 17, 2023 15:00 ET
|
Mental Health Technologies (MHT)
AURORA, Ill., Jan. 17, 2023 (GLOBE NEWSWIRE) -- At Mental Health Technologies (MHT), they bring awareness to mental health concerns daily. However, each year everyone goes from the hustle and bustle...
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
January 09, 2023 07:30 ET
|
GH Research PLC
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND...
Nexstim Receives an Order for Two NBT® Systems from Canada
December 14, 2022 03:45 ET
|
Nexstim Oyj
Press release, Helsinki, 14 December 2022 at 10:45 AM (EET) Nexstim Receives an Order for Two NBT® Systems from Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it...
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
December 12, 2022 07:00 ET
|
Gb Sciences
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Psychiatric Times Announces the Addition of the Anxiety and Depression Association of America to its Strategic Alliance Partnership Program
December 06, 2022 14:15 ET
|
Psychiatric Times™
CRANBURY, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Psychiatric Times™, the #1 psychiatric publication in the United States, today announced that it has added the Anxiety and Depression Association of...
Warning Signs & What to Look for: Anxiety and Depression in Childhood - A Free Webinar from the Brain & Behavior Research Foundation
November 28, 2022 08:37 ET
|
Brain & Behavior Research Foundation
New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Warning Signs & What to Look for: Anxiety and Depression in Childhood”...
neurocare group AG Announces Publication Confirming the Importance of Sleep for Effectiveness of Combined rTMS and CBT for OCD
November 21, 2022 10:00 ET
|
neurocare group AG
MUNICH, Nov. 21, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...